11 Sep 2023

Pharma Focus Asia, Issue 52, 2023 – Human Challenge Trials: Establishing early risk-benefit in development of vaccines and therapies for infectious diseases

Share this:

Featured on pages 54-56

Other recent posts

Tripledemic Takedown: How Human Challenge Trials are Ideal to Expedite Multivalent Vaccine Development

Introduction The recent rise of the "tripledemic" – the concurrent spread of the influenza virus, SARS-CoV-2 virus, and respiratory syncytial virus (RSV) – is posing significant risks, especially to older...

Human SARS-CoV-2 challenge uncovers local and systemic response dynamics | Nature

If you’re a potential customer, job seeker, health professional or an investor, find out how hVIVO can help you.